Nichola Gale1, David Wasley2, Sioned Roberts3, Karianne Backx2, Annemarie Nelson3, Robert van Deursen4, Anthony Byrne5. 1. School of Healthcare Sciences, College of Biomedical and Life Sciences, Heath Park, Cardiff University, Cardiff, CF14 4XN, UK. galens@cardiff.ac.uk. 2. Cardiff School of Sport, Cardiff Metropolitan University, Cardiff, CF23 6XD, UK. 3. Velindre Cancer Centre, Whitchurch, Cardiff, CF14 2TL, UK. 4. School of Healthcare Sciences, College of Biomedical and Life Sciences, Heath Park, Cardiff University, Cardiff, CF14 4XN, UK. 5. Marie Curie Research Centre (MCPCRC), School of Medicine, Heath Park, Cardiff University, Cardiff, CF14 4XN, UK.
Abstract
PURPOSE: Patients with cancer frequently experience an involuntary loss of weight (in particular loss of muscle mass), defined as cachexia, with profound implications for independence and quality of life. The rate at which such patients' physical performance declines has not been well established. The aim of this study was to determine the change in muscle strength and function over 8 weeks in patients with already established cancer cachexia, to help inform the design and duration of physical activity interventions applicable to this patient group. METHODS: Patients with thoracic and gastrointestinal cancer and with unintentional weight loss of > 5% in 6 months or BMI < 20 plus 2% weight loss were included. Physical and functional assessments (baseline, 4 weeks, 8 weeks) included isometric quadriceps and hamstring strength, handgrip, standing balance, 10-m walk time and timed up and go. RESULTS: Fifty patients (32 male), mean ± SD age 65 ± 10 years and BMI 24.9 ± 4.3 kg/m2, were recruited. Thoracic cancer patients had lower muscle strength and function (p < 0.05). Despite notable attrition, in patients who completed all assessments (8 thoracic and 12 gastrointestinal), there was little change in performance over 8 weeks (p > 0.05). Baseline variables did not differentiate between completers and non-completers (p > 0.05). CONCLUSIONS: More than a third of patients with established cancer cachexia in our study were stable over 8 weeks, suggesting a subgroup who may benefit from targeted interventions of reasonable duration. Better understanding the physical performance parameters which characterise and differentiate these patients has important clinical implications for cancer multidisciplinary team practice.
PURPOSE: Patients with cancer frequently experience an involuntary loss of weight (in particular loss of muscle mass), defined as cachexia, with profound implications for independence and quality of life. The rate at which such patients' physical performance declines has not been well established. The aim of this study was to determine the change in muscle strength and function over 8 weeks in patients with already established cancer cachexia, to help inform the design and duration of physical activity interventions applicable to this patient group. METHODS: Patients with thoracic and gastrointestinal cancer and with unintentional weight loss of > 5% in 6 months or BMI < 20 plus 2% weight loss were included. Physical and functional assessments (baseline, 4 weeks, 8 weeks) included isometric quadriceps and hamstring strength, handgrip, standing balance, 10-m walk time and timed up and go. RESULTS: Fifty patients (32 male), mean ± SD age 65 ± 10 years and BMI 24.9 ± 4.3 kg/m2, were recruited. Thoracic cancer patients had lower muscle strength and function (p < 0.05). Despite notable attrition, in patients who completed all assessments (8 thoracic and 12 gastrointestinal), there was little change in performance over 8 weeks (p > 0.05). Baseline variables did not differentiate between completers and non-completers (p > 0.05). CONCLUSIONS: More than a third of patients with established cancer cachexia in our study were stable over 8 weeks, suggesting a subgroup who may benefit from targeted interventions of reasonable duration. Better understanding the physical performance parameters which characterise and differentiate these patients has important clinical implications for cancer multidisciplinary team practice.
Authors: D Blum; G B Stene; T S Solheim; P Fayers; M J Hjermstad; V E Baracos; K Fearon; F Strasser; S Kaasa Journal: Ann Oncol Date: 2014-02-20 Impact factor: 32.976
Authors: Simone Hummler; Michael Thomas; Belinda Hoffmann; Philipp Gärtner; Martin Zoz; Gerhard Huber; Cornelia M Ulrich; Joachim Wiskemann Journal: Oncol Res Treat Date: 2014-01-24 Impact factor: 2.825
Authors: Bret H Goodpaster; Seok Won Park; Tamara B Harris; Steven B Kritchevsky; Michael Nevitt; Ann V Schwartz; Eleanor M Simonsick; Frances A Tylavsky; Marjolein Visser; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2006-10 Impact factor: 6.053
Authors: Lee W Jones; Rachel-Rose Cohen; Stephanie K Mabe; Miranda J West; Annick Desjardins; James J Vredenburgh; Allan H Friedman; David A Reardon; Emily Waner; Henry S Friedman Journal: J Neurooncol Date: 2009-02-11 Impact factor: 4.130
Authors: Carla M Prado; Michael B Sawyer; Sunita Ghosh; Jessica R Lieffers; Nina Esfandiari; Sami Antoun; Vickie E Baracos Journal: Am J Clin Nutr Date: 2013-08-21 Impact factor: 7.045
Authors: Wiebke Jensen; Freerk T Baumann; Alexander Stein; Wilhelm Bloch; Carsten Bokemeyer; Maike de Wit; Karin Oechsle Journal: Support Care Cancer Date: 2014-02-15 Impact factor: 3.603
Authors: Guro Birgitte Stene; Trude Rakel Balstad; Anne Silja M Leer; Asta Bye; Stein Kaasa; Marie Fallon; Barry Laird; Matthew Maddocks; Tora S Solheim Journal: Cancers (Basel) Date: 2019-12-03 Impact factor: 6.639